problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl20085437-11problendo-11011Research ArticleКлиническая эндокринологияClinical endocrinologyКомментарии к результатам исследования ADOPTComments on the results of the ADOPT studyУшкаловаЕ. А.UshkalovaYe. A.probl@endojournals.ru<p>Российский университет Дружбы народов</p>Россия<p>Peoples' Friendship University of Russia</p>Russian Federation200815062008543ТОМ 54, №3 (2008)711Copyright &#x00A9; Ушкалова Е.А., 20082008Ушкалова Е.А.Ushkalova Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/11011

Сахарный диабет 2-го типа (СД2) — "неинфекционная эпидемия" нашего времени — уже сейчас занимает одну из лидирующих позиций в мире по показателю тяжести заболевания (смерть + инвалидизация). Смертность больных СД2 в 2,3 раза превышает смертность среди населения в целом. Ежегодно СД является причиной гибели примерно 3,8 млн человек.

Type 2 diabetes mellitus (T2DM) - the "non-infectious epidemic" of our time - now occupies one of the leading positions in the world in terms of the severity of the disease (death + disability). Mortality of patients with T2DM is 2.3 times higher than mortality among the general population. Every year, diabetes is the cause of death of approximately 3.8 million people.

сахарный диабетинвалидизациясмертностьdiabetesdisabilitymortalityReferencesКарпов О. И. // Рус. мед. журн. - 2006. - № 26. - Р. 3-6.Карпов О. И. // Рус. мед. журн. - 2006. - № 26. - Р. 3-6.Al-Ozpiri Е., Sibal L., Лоте Р. // Diabetes Саге. - 2007. - Vol. 30. - Р. 1677-1680.Al-Ozpiri Е., Sibal L., Лоте Р. // Diabetes Саге. - 2007. - Vol. 30. - Р. 1677-1680.American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997 // Diabetes Care. - 199S. - Vol. 21. - P. 296-309.American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997 // Diabetes Care. - 199S. - Vol. 21. - P. 296-309.Bloomgarden Z. T. // Diabetes Care. - 2007. - Vol. 30. - P. 2401-2403.Bloomgarden Z. T. // Diabetes Care. - 2007. - Vol. 30. - P. 2401-2403.The CDC Diabetes Cost-Effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol reduction for type 2 diabetes // J. A. M. A. - 2002. - Vol. 287. - P. 2542-2551The CDC Diabetes Cost-Effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol reduction for type 2 diabetes // J. A. M. A. - 2002. - Vol. 287. - P. 2542-2551Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes // N. Engl. J. Med. - 2005. - Vol. 353. - P. 2643-2653.Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes // N. Engl. J. Med. - 2005. - Vol. 353. - P. 2643-2653.Global Prevalence of Diabetes Set to Top 380 Million by 2025 News, Reuters Health Information, December 2006.Global Prevalence of Diabetes Set to Top 380 Million by 2025 News, Reuters Health Information, December 2006.Grey A., Bolland M. Gamble G. et al. // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92, N 4. - P. 1305-1310.Grey A., Bolland M. Gamble G. et al. // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92, N 4. - P. 1305-1310.Kahn S. E., Haffner S. M., Ifeise M. A. et al. // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2427-2443.Kahn S. E., Haffner S. M., Ifeise M. A. et al. // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2427-2443.Kannel W. В., McCee D. L. // Circulation. - 1979. - Vol. 59. -P. 8-13.Kannel W. В., McCee D. L. // Circulation. - 1979. - Vol. 59. -P. 8-13.Lipscombe L. L., Comes Т., Levesque L. E. et al. // J. A. M. A. - 2007. - Vol. 293. - P. 2634-2643.Lipscombe L. L., Comes Т., Levesque L. E. et al. // J. A. M. A. - 2007. - Vol. 293. - P. 2634-2643.Muhammad S. // Compcnd. Contin. Educ. Dent. - 2004. - Vol. 25, N 3. - P. 195-193; 200; 202.Muhammad S. // Compcnd. Contin. Educ. Dent. - 2004. - Vol. 25, N 3. - P. 195-193; 200; 202.Murray С. J., Lopez A. D. The Global Burden of Disease. - Geneva, 1996.Murray С. J., Lopez A. D. The Global Burden of Disease. - Geneva, 1996.Nissen S. E., H'olski К. // N. Engl. J. Med. - 2007. -Vol. 356, N 24. - P. 2457-2471.Nissen S. E., H'olski К. // N. Engl. J. Med. - 2007. -Vol. 356, N 24. - P. 2457-2471.Singh A., Blackwell J., Neher J. // J. Fam. Pract. - 2005. -Vol. 54, N 4. - P. 370-372.Singh A., Blackwell J., Neher J. // J. Fam. Pract. - 2005. -Vol. 54, N 4. - P. 370-372.UKPDS Group: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS 41): United Kingdom Prospective Diabetes Study Group // Br. Med. J. - 2000. - Vol. 320. - P. 1373-1378.UKPDS Group: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS 41): United Kingdom Prospective Diabetes Study Group // Br. Med. J. - 2000. - Vol. 320. - P. 1373-1378.United Kingdom Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1993. - Vol. 352. - P. 837-853.United Kingdom Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1993. - Vol. 352. - P. 837-853.Viberti C., Kahn S. Е., Greene D. A. et al. // Diabetes Care. - 2002. - Vol. 25. - P. 1737-1743.Viberti C., Kahn S. Е., Greene D. A. et al. // Diabetes Care. - 2002. - Vol. 25. - P. 1737-1743.Yaturu S., Bryant В., Jain S. K. // Diabetes Care. - 2007. - Vol. 30.-P. 1574-1576.Yaturu S., Bryant В., Jain S. K. // Diabetes Care. - 2007. - Vol. 30.-P. 1574-1576.

The authors declare that there are no conflicts of interest present.